Does omeprazole influence the antiplatelet action of clopidogrel? OCLA study Review article
Article Sidebar
Published:
Jun 30, 2009
Keywords:
omeprazole, clopidogrel, CYP2C19
Main Article Content
Abstract
In previous observational studies was affirmed that antiplatelet action of clopidogrel is reduced in patients receiving proton pump inhibitor treatment. The postulated mechanism is that omeprazole (and some others medicines from this group) inhibits the isoenzyme 2C19 of cytochrome P450 (CYP2C19), which participates in transformation of clopidogrel to its active metabolite. The aim of the OCLA study (Omeprazole CLopidogrel Aspirin Study) was the assessment of influence of omeprazole on antiplatelet action of clopidogrel in patients undergoing elective coronary stent implantation.
Article Details
How to Cite
Chybowska, B. (2009). Does omeprazole influence the antiplatelet action of clopidogrel? OCLA study. Medycyna Faktow (J EBM), 2(2(3), 16-18. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2660
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Gilard M., Arnaud B., Cornily J. et al.: Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J. Am. Coll. Cardiol. 2008; 51: 256-60.
2. Barragan P., Bouvier J., Roquebert P. et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter. Cardiovasc. Interv. 2003; 59: 295-302.
2. Barragan P., Bouvier J., Roquebert P. et al.: Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter. Cardiovasc. Interv. 2003; 59: 295-302.